(Q42204820)

English

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study

scientific article published on 18 July 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Safety, tolerability and immunogenicity of GS-4774, a hepatitis B virus-specific therapeutic vaccine, in healthy subjects: a randomized study (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hepatitis B virus

1 reference

based on heuristic

inferred from title

therapeutic vaccine

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

author name string

Anuj Gaggar

1

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Claire Coeshott

2

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

David Apelian

3

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Timothy Rodell

4

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Brian R Armstrong

5

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Gong Shen

6

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

G Mani Subramanian

7

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

John G McHutchison

8

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

language of work or name

0 references

publication date

18 July 2014

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

4925-4931

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

Hepatitis B virus immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

The immune response during hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

New insights into how HBV manipulates the innate immune response to establish acute and persistent infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Update in the management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Anti-Saccharomyces cerevisiae mannan antibodies (ASCA) of Crohn's patients crossreact with mannan from other yeast strains, and murine ASCA IgM can be experimentally induced with Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Immune sensitization to yeast antigens in ASCA-positive patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Class II MHC peptide loading by the professionals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.07.027

7 January 2021

Identifiers

10.1016/J.VACCINE.2014.07.027

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42204820&oldid=1935932825"